Comprehensive comparison between azacytidine and decitabine treatment in an acute myeloid leukemia cell line
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1868-7083
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Comprehensive comparison between azacytidine and decitabine treatment in an acute myeloid leukemia cell line ; volume:14 ; number:1 ; day:11 ; month:9 ; year:2022 ; pages:1-20 ; date:12.2022
Clinical epigenetics ; 14, Heft 1 (11.9.2022), 1-20, 12.2022
- Creator
-
Aumer, Tina
Gremmelmaier, Constanze B.
Runtsch, Leander S.
Pforr, Johannes C.
Yeşiltaç, G. Nur
Kaiser, Stefanie
Traube, Franziska R.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s13148-022-01329-0
- URN
-
urn:nbn:de:101:1-2022112821234013847251
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:36 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Aumer, Tina
- Gremmelmaier, Constanze B.
- Runtsch, Leander S.
- Pforr, Johannes C.
- Yeşiltaç, G. Nur
- Kaiser, Stefanie
- Traube, Franziska R.
- SpringerLink (Online service)
Other Objects (12)
Venetoclax with decitabine versus decitabine monotherapy in elderly acute myeloid leukemia: a propensity score-matched analysis
The Clinical Value of Decitabine Monotherapy in Patients with Acute Myeloid Leukemia
The clinical value of decitabine monotherapy in patients with acute myeloid leukemia
The predictive value of BTG1 for the response of newly diagnosed acute myeloid leukemia to decitabine
Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab
Gene expression profiling based identifications of potential prognostic molecular markers in decitabine treated acute myeloid leukemia
Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab
Decitabine shows anti-acute myeloid leukemia potential via regulating the miR-212-5p/CCNT2 axis
Quantitative proteomic analysis of histone modifications in decitabine sensitive and resistant leukemia cell lines
Oral decitabine/cedazuridine versus intravenous decitabine for acute myeloid leukaemia: A randomised, crossover, registration, pharmacokinetics study
Monosomal karyotype and chromosome 17p loss or TP53 mutations in decitabine-treated patients with acute myeloid leukemia
Monosomal karyotype and chromosome 17p loss or TP53 mutations in decitabine-treated patients with acute myeloid leukemia
Venetoclax with decitabine versus decitabine monotherapy in elderly acute myeloid leukemia: a propensity score-matched analysis
The Clinical Value of Decitabine Monotherapy in Patients with Acute Myeloid Leukemia
The clinical value of decitabine monotherapy in patients with acute myeloid leukemia
The predictive value of BTG1 for the response of newly diagnosed acute myeloid leukemia to decitabine
Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab
Gene expression profiling based identifications of potential prognostic molecular markers in decitabine treated acute myeloid leukemia
Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab
Decitabine shows anti-acute myeloid leukemia potential via regulating the miR-212-5p/CCNT2 axis
Quantitative proteomic analysis of histone modifications in decitabine sensitive and resistant leukemia cell lines
Oral decitabine/cedazuridine versus intravenous decitabine for acute myeloid leukaemia: A randomised, crossover, registration, pharmacokinetics study
Monosomal karyotype and chromosome 17p loss or TP53 mutations in decitabine-treated patients with acute myeloid leukemia
Monosomal karyotype and chromosome 17p loss or TP53 mutations in decitabine-treated patients with acute myeloid leukemia
Venetoclax with decitabine versus decitabine monotherapy in elderly acute myeloid leukemia: a propensity score-matched analysis
The Clinical Value of Decitabine Monotherapy in Patients with Acute Myeloid Leukemia
The clinical value of decitabine monotherapy in patients with acute myeloid leukemia
The predictive value of BTG1 for the response of newly diagnosed acute myeloid leukemia to decitabine
Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab
Gene expression profiling based identifications of potential prognostic molecular markers in decitabine treated acute myeloid leukemia
Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab
Decitabine shows anti-acute myeloid leukemia potential via regulating the miR-212-5p/CCNT2 axis
Quantitative proteomic analysis of histone modifications in decitabine sensitive and resistant leukemia cell lines
Oral decitabine/cedazuridine versus intravenous decitabine for acute myeloid leukaemia: A randomised, crossover, registration, pharmacokinetics study
Monosomal karyotype and chromosome 17p loss or TP53 mutations in decitabine-treated patients with acute myeloid leukemia